



ORIGINAL ARTICLE

Description of patients excluded for Mohs surgery after pre-surgical evaluation: data from the Regesmohs Spanish registry[☆]



V. Ruiz-Salas,^{a,*} J.R. Garcés,^{a,b} T. Alonso-Alonso,^c M.A. Rodríguez-Prieto,^c A. Toll-Abelló,^d E. Eusebio Murillo,^e R. Miñano,^f J.L. López-Estebarez,^f O. Sanmartín-Jiménez,^g C. Guillén Barona,^g I. Allende Markixana,^h A. Alfaro Rubio,ⁱ Y. Delgado Jiménez,^{j,k} R. Navarro,^k L. Barchino Ortiz,^l P. Lázaro Ochaíta,^l E. Vilarasa,^{a,b} C. Ciudad Blanco,^{l,m} H. Vázquez-Veiga,ⁿ J.L. Artola Igarza,^ñ M.L. Alonso,^o I. García-Doval,^p M.A. Descalzo,^p P. Redondo Bellón^q

^a Hospital de la Santa Creu i Sant Pau, Barcelona, España

^b Clínica Teknon, Barcelona, España

^c Complejo Asistencial Universitario de León, León, España

^d Hospital del Mar, Barcelona, España

^e Complejo Hospitalario Universitario de Guadalajara, Guadalajara, España

^f Fundación Hospital de Alcorcón, Madrid, España

^g Instituto Valenciano de Oncología, Valencia, España

^h Hospital Universitario de Cruces, Barakaldo, España

ⁱ Hospital Manises, Valencia, España

^j Hospital Universitario Quirón, Madrid, España

^k Hospital de la Princesa, Madrid, España

^l Hospital la Zarzuela, Madrid, España

^m Hospital Gregorio Marañón, Madrid, España

ⁿ Complejo Hospitalario Universitario de Santiago, Santiago, España

^ñ Hospital de Galdakao, Galdakao, España

^o Hospital La Paz, Madrid, España

^p Research Unit. Fundación Piel Sana, Academia Española de Dermatología y Venereología, Madrid, España

^q Clínica Universidad de Navarra, Pamplona, España

Received 26 September 2017; accepted 23 November 2017

Available online 15 March 2018

KEYWORDS

Mohs surgery;
Vismodegib;
Basal cell carcinoma

Abstract

Background: Regesmohs registry is a nationwide registry including patients evaluated for Mohs surgery in 17 Spanish centres since July 2013. Given that Mohs surgery is the therapy with best results for high risk basal cell carcinoma (BCC) and other skin tumours, we wanted to describe

[☆] Please cite this article as: Ruiz-Salas V, Garcés JR, Alonso-Alonso T, Rodríguez-Prieto MA, Toll-Abelló A, Eusebio Murillo E, et al. Description of patients excluded for Mohs surgery after pre-surgical evaluation: data from the Regesmohs Spanish registry. Actas Dermosifiliogr. 2018;109:346–350.

* Corresponding author.

E-mail address: VRuizS@santpau.cat (V. Ruiz-Salas).

the reasons that lead to some patients being excluded from this therapy and the alternative treatments that they received. These data may be useful to avoid excluding patients for Mohs surgery use, to estimate the healthcare demand of these patients and the demand for Hedgehog inhibitors therapy in this group.

Objective: To describe patients excluded for Mohs surgery after pre-surgical assessment, and the treatments that they received.

Methods: Regesmohs includes all consecutive patients assessed for Mohs surgery in the participating centres, collecting data on patient characteristics, intervention, and short and long-term results. Patients excluded for Mohs surgery after pre-surgical evaluation were described.

Results: 3011 patients were included in Regesmohs from July 2013 to October 2016. In 85, Mohs surgery was not performed as they were considered inadequate candidates. 67 had BCC. Reasons for exclusion were: medical contraindication (27.1%, n=23) low-risk tumour in (18.8%, n=16) and giant tumour and bone invasion (15.3%, n=13). Only 1 patient (1.2%) showed lymph node involvement and no patients had visceral metastases. Of the 85 excluded patients, 29 (34.1%) were treated with conventional surgery, 24 (28.3%) with radiotherapy, 4 (4.7%) with inhibitors of the Hedgehog pathway (only indicated for BCC), and 2 (2.4%) received palliative care. We had no follow-up data on 14 patients (16.5%).

Conclusion: Medical comorbidities were the most common reason for withholding Mohs surgery. Withholding therapy on the basis of distant extension is uncommon. Most excluded patients received simpler therapies: conventional surgery or radiotherapy, with hedgehog inhibitors being a new option.

© 2017 Elsevier España, S.L.U. and AEDV. All rights reserved.

PALABRAS CLAVE

Cirugía de Mohs;
Vismodegib;
Carcinoma
basocelular

Descripción de pacientes no aptos para ser sometidos a cirugía de Mohs tras valoración prequirúrgica: datos del registro español Regesmohs

Resumen

Antecedentes: El registro Regesmohs es un registro de ámbito nacional, de pacientes evaluados y sometidos a una cirugía de Mohs, en 17 centros españoles, desde julio de 2013. Como la cirugía de Mohs es el tratamiento que mejores resultados da para el manejo del carcinoma de células basales (CCB) de alto riesgo y otros tumores de la piel, queríamos describir los motivos por los que algunos pacientes fueron considerados no aptos para ser sometidos a este tratamiento y qué tratamientos alternativos recibieron. Estos datos pueden ser útiles para evitar excluir a pacientes aptos para ser sometidos a una cirugía de Mohs, para calcular la demanda que estos pacientes generan a nivel sanitario, así como la demanda que hay de tratamientos de inhibidores de la vía de Hedgehog en dicho grupo de pacientes.

Objetivo: Describir a aquellos pacientes que fueron considerados no aptos para ser sometidos a una cirugía de Mohs tras valoración prequirúrgica y los tratamientos que recibieron.

Métodos: Regesmohs incluye a todos los pacientes consecutivos para ser sometidos a una cirugía de Mohs en los centros participantes, recogiendo datos sobre las características de los pacientes, las intervenciones y los resultados a corto y largo plazo. Se hizo una descripción de los pacientes considerados no aptos para ser sometidos a una cirugía de Mohs tras valoración prequirúrgica.

Resultados: Tres mil once pacientes fueron incluidos en el registro Regesmohs entre julio de 2013 y octubre de 2016. En 85 pacientes no se realizó cirugía de Mohs porque se consideraron candidatos inadecuados. Sesenta y siete pacientes presentaban CCB. Las razones para ser considerado paciente no apto fueron: contraindicaciones médicas (27,1%, n=23), tumores de bajo riesgo (18,8%, n=16) y tumores gigantes e invasión ósea (15,3%, n=13). Solo un paciente (1,2%) reveló compromiso de ganglios linfáticos y ningún paciente metástasis visceral. De los 85 pacientes considerados no aptos 29 (34,1%) fueron sometidos a cirugía convencional, 24 (28,3%) a radioterapia, 4 (4,7%) a inhibidores de la vía de Hedgehog (solo indicado para el CCB) y 2 (2,4%) a tratamiento paliativo. No hubo datos de seguimiento de 14 pacientes (16,5%).

Conclusión: Las comorbilidades médicas fueron la razón más habitual para retener la cirugía de Mohs. Retener un tratamiento en función de una propagación a lugares distantes no es algo habitual. La mayoría de los pacientes considerados no aptos recibieron tratamientos más sencillos: cirugía convencional o radioterapia, siendo los inhibidores de la vía de Hedgehog una opción novedosa.

© 2017 Elsevier España, S.L.U. y AEDV. Todos los derechos reservados.

Introduction

Mohs micrographic surgery (MMS) is a technique used to treat various types of skin cancer, performed in many public and private Spanish hospitals. The experience published in the literature related to this technique, including long series of cases and an extensive follow-up period, mainly comes from the US, Australia, Latin America and other European countries.¹⁻⁵

The Spanish Registry of Mohs Surgery (Regesmohs) collects data on patients assessed for Mohs surgery in 17 national centres from July 2013 with the aim of obtaining a representative description of Mohs surgery in Spain.⁶ Given that Mohs surgery is probably the therapy with best results for high risk basal cell carcinoma⁷ and probably other skin tumours, we wanted to describe the reasons that lead to some patients being excluded from this therapeutic option and the alternative therapy that these patients received. These data will help describe the approach to complex tumours, might be useful to detect preventable factors that could increase the use of Mohs surgery, and will also be helpful to estimate the need for alternative treatments. We have not found previous studies describing these patients.

Our objective was to describe the characteristics of patients excluded for Mohs surgery after pre-surgical assessment in Regesmohs, and the treatments that they received.

Materials and methods

The Spanish Registry of Mohs Surgery (Regesmohs) is a prospective cohort study collecting data from 17 centres that perform at least one weekly MMS. These centres represent a very high percentage of those that perform MMS in Spain. Participating centres include all consecutive patients evaluated for performing MMS. In this registry, data related to patient characteristics and their intervention, short-term results (in a postsurgical visit) and long-term results are collected. Patients should have an annual postsurgical visit to describe their long-term evolution. Some patients were candidates for MMS, but were excluded on their pre-surgical visit. These are the patients that we describe in this paper.

The information is collected through an online data collection system (OpenClinica, version 3.1) of the Research Unit of the Spanish Academy of Dermatology. All investigators use a common dictionary data to ensure uniformity in the definition of the variables. The registry has a continuous online monitoring system that detects missing or inconsistent data. Regesmohs received ethical approval from *Comité Ético de Investigación Clínica Universidad de Navarra* (EO11/2013) and all patients gave their informed consent to participate.

Statistical analysis consisted of descriptive analysis of demographic data and clinical characteristics of patients. The qualitative variables were expressed as absolute values and percentages. Quantitative variables were expressed as means and standard deviations. It was performed using Stata (StataCorp. 2015 Release 14.2).

Results

3011 patients have been included in the registry from July 2013 to October 2016. Of these, 85 patients were considered inadequate candidates for MMS. The median age of these patients was 83.2 years (p25=75.1; p75=88.4), with a moderate predominance of males (56.5%, n = 48). Most patients came from the catchment area of each centre (88.2%, n=75), while 11.8% (n = 10) patients were referred from other areas. Few patients 3.5% (n = 3) had some type of immunosuppression, 16.5% (n = 14) had diabetes mellitus and 4.7% (n = 4) were diagnosed with some type of multiple tumours syndrome. The median tumour size was 11 mm of major axis (5-24) and 10 mm of minor axis (4-18). The median time of tumour progression from diagnosis to treatment decisions was 17.8 months (P25-P75: 7.7-39.7).

Patients that received MMS (2926) were in median age 70.7 years old (58.8-79.8), with a percentage of males of 51.0% (n = 1493) and an median tumour size of 10 mm (6-18). Moreover 955 (32.6%) patients received some type of previous surgery before MMS. Compared to patients that received MMS, patients excluded were older, with a higher percentage of males and a higher average tumour size.

Most excluded patients had basal cell carcinoma (BCC) (78.8%, n = 67) and 14.1% had squamous cell carcinoma (n=12). Detailed histological subtypes are described in [Table 1](#). Most of the excluded tumours were primary (i.e. non-recurrent) (67.1%, n = 57) and located on the face and scalp (91.8%, n = 78), where the nose was the most common location (37.7% n = 32).

36.5% of the patients (n=31) had received a previous therapy ([Table 2](#)), most commonly surgery. The median time between the application of a previous surgical treatment (cryotherapy / curettage / Simple excision) until the new clinical assessment and exclusion from the registry was 6.5 months (P25-P75: 2.9-17.5).

Only 1 patient (1.2%) showed lymph node involvement and no patients had visceral metastases.

The main reasons for withholding Mohs surgery was the existence of some medical contraindication (27.1%, n = 23) and the presence of a low-risk tumour in 18.8% (n = 16). The presence of a giant tumour and deep invasion represented 15.3% (n = 13) of the total ([Table 3](#)).

Of the 85 excluded patients, 29 (34.1%) were treated with conventional surgery, 24 (28.3%) with radiotherapy, 4 (out of the 67 BCC (6.0%)) (4.7%) with inhibitors of the Hedgehog pathway (3 with locally advanced BCC and invasion of deep structures and 1 with Gorlin syndrome), and 2 (2.4%) received palliative care. We had no follow-up data on 16 patients (18.8%).

Discussion

We have found that medical contraindications, or the overall situation of the patient, is the most common reason for withholding Mohs surgery in our patients.

Some patients (18 /3011) were considered inadequate for Mohs surgery because the tumour was too small or of low risk, probably indicating an inadequate referral. The 7 tumours excluded because of their location could also belong to this group.

Table 1 Frequency and percentage of tumours histological subtypes.

Histological Diagnosis	Frequency	Percentage
Histologically nonaggressive BCC	22	25.9
Infiltrating BCC	20	23.5
Morpheaform BCC	15	17.7
Keratinising/metatypical BCC	7	8.2
Histologically nonaggressive SCC	4	4.7
Micronodular BCC	3	3.5
Infiltrating SCC	3	3.5
Undifferentiated SCC	2	2.4
Perineural/perivascular invasion SCC	2	2.4
Atypical fibroxanthoma/malignant fibrous histiocytoma	2	2.4
Other	2	2.4
Sclerosing SCC	1	1.2
Acral lentiginous melanoma	1	1.2
Sebaceous carcinoma	1	1.2
Total	85	100.0

BCC: basal cell carcinoma; SCC: squamous cell carcinoma;.

Table 2 Previous treatments received by patients excluded for Mohs surgery.

Treatment	Frequency	Percentage
Cryotherapy	1	1.2
Curettage / electrocoagulation	1	1.2
Photodynamic therapy	1	1.2
Imiquimod	1	1.2
Fluoropyrimidines	0	0
Hedgehog inhibitors	0	0
Direct closure	19	22.4
Flap	8	9.3
Graft	2	2.4
Mohs surgery	1	1.2
Radiotherapy	1	1.2
Total*	31	36.5

* Four Patients received 2 previous treatments.

8.2% (n=7) were excluded due to deep structures invasion, and 7.1% (n=6) because the tumour was too large. The presence of disseminated disease was an uncommon contraindication.

Perhaps because of these facts, most patients excluded from MMS are derived to simpler therapeutic measures, such

Table 3 Reasons for contraindicating Mohs surgery.

Reason for contraindication	Frequency	Percentage
Patient medical condition	23	27.1
Low risk tumour	16	18.8
Miscellaneous*	12	14.1
Patient refusal to intervention	10	11.8
Location	7	8.2
Bone, perineural or orbital invasion	7	8.2
Size: too big	6	7.1
Size: small	2	2.4
Multiple tumours	2	2.4
Total	85	100.0

* Miscellaneous causes include administrative causes, multicentric tumours, and patients with no tumour in biopsy.

as conventional surgery (34%) or radiotherapy (28%). Few patients received treatment with vismodegib. However, this estimation has limited validity as this drug was licensed in 2016, and it is only indicated for locally advanced and metastatic BCC

Although the use criteria for appropriate use of Mohs surgery have been described,⁸ we have not found in the literature previous descriptions of those patients considered inadequate for Mohs surgery and the treatments that they received.

Our registry has the advantage of being highly representative of current MMS in Spain, because it prospectively records the activity of most centres performing this technique. One limitation is that the patterns of referral, surgical ability and availability of alternative therapies might be different in different countries, so the results might not be fully generalizable to other contexts. The main limitations of our study is that we have only taken into account those patients that have been initially referred for Mohs surgery and excluded in their pre-surgical visit. Many patients could have been referred to a different therapy without this pre-surgical evaluation. However, we feel that the results are informative and relevant, and that these data might be useful for estimating the healthcare demand associated with skin tumours treated with MMS. Medical comorbidities are the main reason for contraindicating Mohs surgery, and it is possible that this limitation might be overridden by improved perioperative care.

Funding sources

Regesmohs is promoted by the Spanish Academy of Dermatology, with the financial support of Roche Farma SA.

Acknowledgement

The following members of Regesmohs have participated in data collection: Luis Miguel Valladares (Complejo Asistencial Universitario de León), Eduardo Nagore Enguidanos, Beatriz Llombart Cussac and Celia Requena Caballero (Instituto

Valenciano de Oncología) Luis Hueso Gabriel, Antonio Martorell (H. Manises), Victoriano Morales Gordillo (H. Quirón, Pozuelo, Madrid), Raquel Navarro Tejedor (H de la Princesa, Madrid) M Mayoral (Hospital La Paz, Madrid) R Suárez (H Gregorio Marañón, Madrid) M^a José Seoane Pose (CHU Santiago). We also thank other members of participating departments that have helped with the registry.

References

1. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. *J Am Acad Dermatol*. 2005;53:445–51.
2. Leibovitch I, Huilgol SC, Franzco DS, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia. Experience over 10 years. *J Am Acad Dermatol*. 2005;53:253–60.
3. Macfarlane L, Waters A, Evans A, Affleck A, Fleming C. Seven years experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards. *Clin Experim Dermatol*. 2013;38:262–9.
4. Flohil SC, van Dorst AM, Nijsten T, Martino Neumann HA, Munte K. Mohs micrographic surgery for basal cell carcinomas: Appropriateness of 'Rotterdam' criteria and predictive factors for three or more stages. *J Eur Acad Dermatol Venereol*. 2013;27:1228–35.
5. Angulo J, Serra-Guillén C, Traves V, Botella-Estrada R, San Martín O, Llombart B, et al. Mohs micrographic surgery for repeat excision of basal cell carcinomas on the head with positive margins. *Actas Dermosifiliogr*. 2011;102:794–804.
6. Ruiz-Salas V, Garcés JR, Miñano Medrano R, Alonso-Alonso T, Rodríguez-Prieto MÁ, López-Estebanz JL, et al. Description of patients undergoing Mohs surgery in Spain: Initial report on data from the Spanish Registry of Mohs Surgery (REGESMOHS). *Actas Dermosifiliogr*. 2015;106:562–8.
7. Van Loo E, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. *Eur J Cancer*. 2014;50:3011–20.
8. Connolly S, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. *J Am Acad Dermatol*. 2012;67:531–50.